The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 2, 2006, Pages 406-410

  Lind, Lars ^a,c   Vessby, Bengt ^b   Sundström, Johan ^a,b,d,e  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d Departments of Medical Sciences and Public Health and Caring Sciences/Geriatrics   (Sweden)

^e NONE   (Sweden)

Author keywords

Apolipoprotein; Insulin resistance; Metabolic syndrome; Myocardial infarction

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; COMMUNITY CARE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FATALITY; FOLLOW UP; GLUCOSE CLAMP TECHNIQUE; HEART INFARCTION; HUMAN; INCIDENCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; STATISTICAL SIGNIFICANCE; BLOOD; CROSS-SECTIONAL STUDY; LONGITUDINAL STUDY; MIDDLE AGED; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL;

AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INSULIN RESISTANCE; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 33644870185     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000197827.12431.d0     Document Type: Article

References (26)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3143-3421.
3. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-419.
4. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis. 2004;173:309-314.
5. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults. Circulation. 2004;110:1245-1250.
6. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men. JAMA. 2002;288:2709-2716.
7. Howard BV Insulin resistance and lipid metabolism. Am J Cardiol. 1999;84:28J-32J.
8. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. 1999. Geneva WHO Part 1: Diagnosis and Classification of Diabetes Mellitus; 1999.
9. Scheffer PG, Bos G, Volwater HG, Dekker JM, Heine RJ, Teerlink T. Associations of LDL size with in vitro oxidizability and plasma levels of in vivo oxidized LDL in Type 2 diabetic patients. Diabet Med. 2003;20:563-567.
10. Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein B/Apolipoprotein A-I in Relation to the Metabolic Syndrome and Change in Carotid Artery Intima-Media Thickness During 3 Years in Middle-Aged Men. Stroke. 2004;35:2248-2252.
11. Sung KC, Hwang ST. Association between insulin resistance and apolipoprotein B in normoglycemic Koreans. Atherosclerosis. 2005;180:161-169.
12. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-2033.
13. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting Apolipoprotein B and Triglyceride Levels as a Useful Predictor of Coronary Heart Disease Risk in Middle-Aged UK Men. Arterioscler Thromb Vasc Biol. 2002;22:1918-1923.
14. Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM). Am Heart J. 2004;148:596-601.
15. Simons LA, Simons J, Friedlander Y, McCallum J. Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis. 2001;159:201-208.
16. Hedstrand H. A study of middle-aged men with particular reference to risk factors for cardiovascular disease. Ups J Med Sci Suppl. 1975;19:1-61.
17. Byberg L, Siegbahn A, Berglund L, McKeigue P, Reneland R, Lithell H. Plasminogen Activator Inhibitor-1 Activity Is Independently Related to Both Insulin Sensitivity and Serum Triglycerides in 70-Year-Old Men. Arterioscler Thromb Vasc Biol. 1998;18:258-264.
18. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
19. Lindblad U, Rastam L, Ranstam J, Peterson M. Validity of register data on acute myocardial infarction and acute stroke: the Skaraborg Hypertension Project. Scand J Soc Med. 1993;21:3-9.
20. Hammar N, Alfredsson L, Rosen M, Spetz CL, Kahan T, Ysberg AS. A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. Int J Epidemiol. 2001;30:S30-S34.
21. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med. 2004;255:188-205.
22. Relimpio F, Losada F, Pumar A, Mangas MA, Morales F, Astorga R. Relationships of apolipoprotein B100 with the metabolic syndrome in Type 2 diabetes mellitus. Diabetes Res Clin Practice. 2002;57:199-207.
23. Chan DC, Watts GF, Barrett PH, O'Neill FH, Thompson GR. Plasma Markers of Cholesterol Homeostasis and Apolipoprotein B-100 Kinetics in the Metabolic Syndrome. Obes Res. 2002;11:591-596.
24. Zhang YL, Hernandez-Ono A, Ko C, Yasunaga K, Huang LS, Ginsberg HN. Regulation of Hepatic Apolipoprotein B-lipoprotein Assembly and Secretion by the Availability of Fatty Acids: I. Differential response to the delivery of fatty acids via albumin or remnant-like emulsion particles. J Biol Chem. 2004;279:19362-19374.
25. Couillard C, Lamarche B, Tchernof A, Prud'homme D, Tremblay A, Bouchard C, Moorjanit S, Nadeau A, Lupien PJ, Despres JP. Plasma high-density lipoprotein cholesterol but not apolipoprotein A-I is a good correlate of the visceral obesity-insulin resistance dyslipidemic syndrome*1. Metabolism. 1996;45:882-888.
26. Pont F, Duvillard L, Florentin E, Gambert P, Verges B. High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study. Int J Obes Relat Metab Disord. 2002;26:1151-1158.